Australian pharmaceutical company CSL announced a strategic overhaul including a workforce reduction of up to 15% and the spin-off of its influenza vaccine business, Seqirus, into an independent entity. This reorganization aims to reduce costs by over $500 million annually, streamline R&D efforts, and improve pipeline productivity. Despite a modest 2% revenue increase in the vaccine segment amid competition and lower U.S. influenza vaccination rates, CSL is positioning its vaccine unit for autonomous strategic direction and market responsiveness by mid-2026.